Tirzepatide + Niacinamide Injection

(Ship Cold)

Available Dosage Strengths

16.6 mg / 2 mg/mL

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

Tirzepatide_Niacinamide Description1-4

Tirzepatide_Niacinamide Injection is a combination of tirzepatide and niacinamide. Tirzepatide is a dual incretin receptor agonist, acting on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, while niacinamide (vitamin B3) contributes to mitochondrial support by assisting with cellular energy conversion, and acts as an antioxidant.

Tirzepatide1-3

Tirzepatide is a once-weekly subcutaneous injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also FDA approved for chronic weight management under the brand name Zepbound in certain populations. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Niacinamide(vitamin B3)5-7

Niacinamide (also known as niacin or nicotinic acid) is a vitamin (vitamin B3) that is an essential nutrient. Niacinamide can be found in bran, yeast, eggs, peanuts, poultry, red meat, fish, whole-grain cereals, legumes, and seeds. It plays a key role in helping the body convert food into energy and protecting against oxidative stress by regulating oxidative enzymes and acting directly as an antioxidant. It is used to treat dermatological diseases, central nervous system diseases, and increased cholesterol levels.

Tirzepatide1-4

Tirzepatide exerts its effects through dual incretin receptor agonism, targeting both:

  1. GIP (Glucose-dependent Insulinotropic Polypeptide) Receptor:

– Enhances insulin secretion

– Reduces glucagon secretion

– Promotes lipid metabolism and may contribute to weight loss

  1. GLP-1 (Glucagon-Like Peptide-1) Receptor:

– Delays gastric emptying

– Reduces appetite

– Stimulates insulin release in a glucose-dependent manner

– Inhibits glucagon release during hyperglycemia

 

Niacinamide 5-7

Niacinamide contributes to supporting mitochondrial function and metabolic pathways through its conversion to NAD⁺/NADP⁺.It is a vital component in the oxidized state of nicotinamide adenine dinucleotide (NAD, or coenzyme 1) and the reduced form of nicotinamide adenine dinucleotide phosphate (NADP, or coenzyme 2). The coenzymes, NAD and NADP) facilitate essential oxidation-reduction reactions. These coenzymes play key roles in glycolysis, pyruvate metabolism, protein and amino acid metabolism, pentose biosynthesis, glycerol metabolism, synthesis of high-energy phosphate bonds, and fatty acid metabolism.

Adverse Reactions1-4

Common 

Most adverse reactions are gastrointestinal in nature and dose-dependent:

  • Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite, abdominal pain
  • Headache, dizziness, and injection site reactions

Contraindications & Precautions1-4

Contraindications:

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • History of serious hypersensitivity to tirzepatide or any component of the formulation

Precautions:

  • Pancreatitis risk: Monitor patients for signs/symptoms (serious abdominal pain)
  • Severe gastrointestinal disease: Use with caution; only if benefit outweighs potential risk.
  • Acute kidney injury: Especially in those with dehydration, vomiting, or diarrhea.
  • Diabetic retinopathy: Rapid improvement in glucose may worsen retinopathy.
  • Use with insulin or secretagogues: Dose adjustment may be necessary to reduce hypoglycemia risk.
  • Pregnancy & Lactation:
- No adequate data; use only if the benefit outweighs potential risk.
 Discontinue at least 1 month prior to a planned pregnancy due to long half-life

Store refrigerated at 36°F to 46°F (2°C – 8°C). Discard within 28 days of puncture or according to the beyond-use date. Do not freeze. Keep out of reach of children.

  1. Clinical Pharmacology powered by Elsevier (ClinicalKey) – Tirzepatide Monograph. https://www.clinicalkey.com

  2. FDA Prescribing Information – Mounjaro® (tirzepatide): https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf

  3. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM. 2022; 387(3):205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

  4. Drucker DJ. “Mechanisms of Action and Therapeutic Application of GLP-1 and GIP.” Cell Metabolism. 2018. https://doi.org/10.1016/j.cmet.2018.06.015
  5. Niacinamide – Professional Monograph; NatMed Pro ; 2025 ; https://naturalmedicines.therapeuticresearch.com/Data/ProMonographs/Niacinamide
  6. Vitamin B3 StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK526107/ February 29, 2024. Accessed June 26, 2025
  7. Clinical Pharmacology powered by Elsevier (ClinicalKey) – Niacinamide Monograph. https://www.clinicalkey.com


This sheet is a summary. It may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088.  A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.

EXPLORE MORE

Related Medications

We deliver your orders fast and with complete discretion, straight to your door.

We're licensed to ship nationwide

Our mission is to elevate compounding industry standards through a unique combination of superior science and service.

Ready to get started?